Talquetamab for previously treated relapsed or refractory multiple myeloma

Talquetmab is in clinical development for the treatment of relapsed or refractory multiple myeloma (MM), in patients who have received at least three prior lines of therapy. MM is a rare type of blood cancer that affects multiple areas of the body and is currently incurable. MM develops in the plasma cells of the bone marrow, which is found inside some of the larger bones, and affects the production of white and red blood cells as well as platelets. MM is a relapsing and remitting cancer and can be treated to give the patient periods that are symptom-free, but it eventually returns and develops resistance to previous treatments (refractory MM). The symptom free periods between relapses eventually become shorter each time until the disease becomes fatal. New treatment options can increase overall survival lengths of patients, giving more options to those who have become refractory to several treatments.